19. The composition of claim 17 or claim 18, wherein affinity for Fc gamma RIIIA is determined using surface plasmon resonance.

20. The composition of any one of claims 17 to 19, wherein Fc gamma RIIIA is selected from Fc gamma RIIIA(V158) and Fc gamma RIIIA(F158).

21. The composition of claim 20, wherein Fc gamma RIIIA is Fc gamma RIIIA(V158).

22. The composition of any one of claims 1 to 21, wherein the afucosylated anti-FGFR2IIIb antibodies bind FGFR2IIIb but do not bind to FGFR2IIIc.

23. A host cell comprising nucleic acid encoding anti-FGFR2IIIb antibodies of any one of claims 1 to 22, wherein the host cell lacks a functional alpha-1,6-fucosyltransferase gene (FUT8) gene.

24. The host cell of claim 23, which is a CHO cell.

25. A method for making afucosylated anti-FGFR2IIIb antibodies, said method comprising culturing the host cell of claim 23 or claim 24 under conditions suitable for expressing nucleic acid encoding anti-FGFR2IIIb antibodies.

26. A method for making afucosylated anti-FGFR2IIIb antibodies, comprising culturing the host cell of claim 23 or claim 24 under conditions suitable for producing afucosylated anti-FGFR2IIIb antibodies.

27. The method of claim 25 or 26, further comprising recovering the anti-FGFR2IIIb antibodies produced by the host cell.

28. The method of any one of claims 25 to 27, wherein at least 95% of the anti-FGFR2IIIb antibodies produced by the host cell are afucosylated.

29. The method of claim 28, wherein fucose is undetectable in the anti-FGFR2IIIb antibodies produced by the host cell.

30. The method of claim 28 or claim 29, wherein fucose is assayed by a method comprising HPLC, capillary electrophoresis, or MALDI-TOF mass spectrometry.

31. A pharmaceutical composition comprising the composition of any one of claims 1 to 22 and a pharmaceutically acceptable carrier.

32. Use of a composition of any one of claims 1-22 or of a pharmaceutical composition of claim 31 in the manufacture of a medicament for treating cancer in an individual in need thereof.

33. The use of claim 32, wherein the cancer is a solid tumor.

34. The use of claim 32 or 33, wherein the cancer is selected from gastric cancer, breast cancer, ovarian cancer, endometrial cancer, pancreatic cancer, or esophageal cancer.

35. The use of claim 34, wherein the cancer is gastric cancer.

36. The use of any one of claims 32 to 35, wherein the cancer overexpresses FGFR2IIIb.

37. The use of claim 36, wherein FGFR2IIIb expression is determined by immunohistochemistry (IHC).

38. The use of claim 36 or claim 37, wherein the cancer does not comprise FGFR2 gene amplification.

39. The use of any one of claims 32 to 37, wherein the cancer comprises an FGFR2 gene amplification.

40. The use of any one of claims 32 to 39, wherein the use further comprises that at least one additional therapeutic agent selected from a platinum agent, paclitaxel, ABRAXANE®, docetaxel, gemcitabine, capecitabine, irinotecan, epirubicin, FOLFOX, FOLFIRI, leucovorin, fluorouracil, mitomycin C, and doxorubicin hydrochloride is to be administered.

41. The use of claim 40, wherein the at least one additional therapeutic agent is a platinum agent and the platinum agent is selected from cisplatin, oxaliplatin, and carboplatin.